Clinical Report: Dana-Farber Team Develops Open-Access Predictive Tool

Overview

The PANGEA-SMM tool significantly improves the prediction of progression in smoldering multiple myeloma compared to existing models. It utilizes dynamic biomarkers to assess risk and can be accessed online for immediate patient monitoring.

Background

Smoldering multiple myeloma (SMM) is a precursor to active multiple myeloma, with some patients at high risk of progression. Accurate risk stratification is crucial for timely intervention, as recent FDA approvals highlight the need for targeted treatment in high-risk patients. Traditional static models often fail to provide timely assessments, necessitating the development of more dynamic tools.

Data Highlights

Key Findings

• PANGEA-SMM outperforms static models like 20/2/20 and IMWG.
• It incorporates dynamic biomarkers for real-time risk assessment.
• The tool can accurately predict progression without needing full medical histories or invasive procedures.
• Four key biomarkers were identified as indicators of imminent progression.
• The tool is freely accessible online for immediate clinical use.

Clinical Implications

Healthcare providers can utilize PANGEA-SMM to enhance monitoring of patients with smoldering multiple myeloma, allowing for timely treatment decisions. This tool can help reduce unnecessary interventions in low-risk patients while ensuring high-risk patients receive appropriate care.

Conclusion

PANGEA-SMM represents a significant advancement in the management of smoldering multiple myeloma, offering a more accurate and accessible method for risk stratification and monitoring.

References

1. Dana-Farber Cancer Institute, Nature Medicine, 2026 -- Enhanced dynamic risk stratification of smoldering multiple myeloma
2. The ASCO Post, 2026 -- Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma
3. The ASCO Post, 2020 -- Two Leading Institutions Collaborate to Advance Treatment of Smoldering Multiple Myeloma
4. The ASCO Post — New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
5. the asco post — Novel Single-Cell Sequencing Blood Test for Multiple Myeloma
6. Cancer Care Ontario -- Treatment of Multiple Myeloma: ASCO–Ontario Health Living Guideline
7. Enhanced dynamic risk stratification of smoldering multiple myeloma | Nature Medicine
8. AQUILA Trial Daratumumab Proves Beneficial in Smoldering Multiple Myeloma - The ASCO Post